Menu
/REGISTER
Montecito
Tolman Wiker
Pac Premier
Fielding
Farmers merchants
Loading...
You are here:  Home  >  Health Care  >  Current Article

FDA decides not to approve Amgen biosimilar, at least for now

By   /   Friday, June 1st, 2018  /   Comments Off on FDA decides not to approve Amgen biosimilar, at least for now

    Print       Email
Amgen’s ABP980, a biosimilar of Genentech's cancer treatment Herceptin, was denied approval by the U.S. Food and Drug Administration, the company announced June 1. The Thousand Oaks biotech giant said it received a complete response letter from the FDA. The letters are sent out if the agency has decided not to approve a drug, containing…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Santa Barbara’s Unity Shoppe closes and lays off 15 employees

Read More →